Comparison · NCT01032070-sae
Erlotinib vs Etoposide: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Erlotinib vs Etoposide: serious adverse events. Trial comparisons, record NCT01032070-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01032070-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.462 | 0.232 | 0.709 | wilson | |
| Risk in group 2 | 0.417 | 0.193 | 0.68 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0449 | -0.305 | 0.378 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.11 | 0.455 | 2.7 | log | |
| Odds ratio, group 1 over group 2 | 1.2 | 0.246 | 5.84 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Erlotinib than on Etoposide | 22.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Erlotinib | Erlotinib was administered orally at a dose of 85 mg/m\^2 per day continuously until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity. | 6 | 13 | EG000 |
| Group 2 | Etoposide | Etoposide 50 mg/m\^2 per day was administered orally for 21 days followed by a 7-day rest period until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity. | 5 | 12 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the date of first dose of study drug until 30 days after the last dose. The median time on treatment was 52 days for erlotinib and 58 days for etoposide.
Source ClinicalTrials.gov
Trial
- Title
- Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
- NCT number
- NCT01032070
- Phases
- PHASE2
- Conditions
- Recurrent or Refractory Pediatric Ependymoma
- Interventions
- erlotinib, etoposide
- Lead sponsor
- OSI Pharmaceuticals
- Results first posted
- 2014-01-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01032070?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01032070-sae